Mortality Rate and Biomarker Expression Within COVID-19 Patients Who Develop Acute Ischemic Stroke: a Systematic Review and meta-analysis

Yassin, Ahmed; Ghzawi, Ansam; Al-Mistarehi, Abdel-Hameed; El‐Salem, Khalid; Benmelouka, Amira Yasmine; Sherif, Ahmed; BenhadjDahman, Nesrine; AlAdamat, Nameer; Jemel, Amine; Negida, Ahmed; Abdelmonem, Mohamed

doi:10.2144/fsoa-2021-0036

Cited by 14 publications

(11 citation statements)

References 60 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inflammatory and coagulatory markers like D-dimer, LDH, erythrocyte sedimentation rate (ESR), and CRP were independently associated with the occurrence of ischemic stroke in COVID-19 ( 92 , 93 ), while higher age, diabetes mellitus, and hypertension were found not to be significant predictors of stroke in this population, despite being known predictors of non-COVID-19 stroke ( 93 ). Levels of lymphocytes, procalcitonin, and creatinine were higher in COVID-19 stroke patients ( 94 ). S100B was higher in patients with mild and severe COVID-19 than in healthy controls, and may be a marker of disease severity ( 95 ).…”

Section: Diagnostic and Prognostic Value Of Biomarkersmentioning

confidence: 96%

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count, neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer, brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of these biomarkers can be readily used to predict disease severity, hospitalization, intensive care unit (ICU) admission, and mortality, while others, such as metabolomic and proteomic analysis, have not yet translated to clinical practice. This narrative review aims to identify laboratory biomarkers that have shown significant diagnostic and prognostic value for risk stratification in COVID-19 and discuss the possible clinical application of novel analytic strategies, like metabolomics and proteomics. Future research should focus on identifying a limited but essential number of laboratory biomarkers to easily predict prognosis and outcome in severe COVID-19.

show abstract

Section: Diagnostic and Prognostic Value Of Biomarkersmentioning

confidence: 96%

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The COVID-19 pandemic and its associated precautionary measures have negatively impacted life in all possible ways [ 2 , 3 , 4 , 5 , 6 ]. In addition to the respiratory manifestation that COVID-19 mainly presents with, other manifestations and complications of the infection are vast and could include cardiovascular, thromboembolic, and neurological ones [ 7 , 8 , 9 , 10 , 11 ]. In addition, COVID-19 has considerable psychological effects on patients and the general public as a whole [ 12 , 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Prevalence Estimates and Risk Factors of Anxiety among Healthcare Workers in Jordan over One Year of the COVID-19 Pandemic: A Cross-Sectional Study

Yassin

Al-Mistarehi

El‐Salem

et al. 2022

IJERPH

Self Cite

View full text Add to dashboard Cite

This study investigates the changes in prevalence estimates, severity, and risk factors of anxiety among healthcare workers (HCWs) over the first year of the COVID-19 pandemic. A survey was distributed among HCWs using snowball sampling, collecting their socio-demographics, occupation, and anxiety symptoms as measured by the Generalized Anxiety Disorder-7 (GAD-7) scale. It was distributed one month after the pandemic’s onset in Jordan between 15 and 30 April 2020 (onset group) and after one year between 15 and 30 March 2021 (one-year group). A total of 422 HCWs were included (211 in each group). The one-year group reported a higher risk of GAD (30.8% vs. 16.6%; p = 0.001), a higher mean (SD) GAD-7 score (7.94 (5.29) vs. 6.15 (4.15); p < 0.001), and more severe symptoms (p = 0.003). Univariate analyses showed that participants who were younger, women, unmarried, had lower monthly incomes, underwent testing for COVID-19, had higher contact with COVID-19 patients, did not receive special education, and were unsatisfied with the institutional COVID-19 preparedness scored higher on the GAD-7 scale and had more severe symptoms than their counterparts in both groups. Unlike the onset group, occupation as a physician, COVID-19 infection history, and perception of remarkable changes in work were associated with higher anxiety scores and severity among the one-year group. The COVID-19 vaccine was a relative protective action. Logistic regression analyses showed that the female gender was a risk factor for developing GAD at the pandemic onset, while poor satisfaction with institutional preparedness was a significant GAD risk factor in the one-year group. Low monthly income and lack of special education were the shared risk factors for GAD in both groups. This study reveals a significant rise in anxiety among HCWs over a year of the COVID-19 pandemic and shows the vulnerable sub-groups who likely need psychological interventions.

show abstract

“…Zimmerman et al described the prognostic value of the first CRP measurement of patients hospitalized due to H1N1 influenza [ 32 ]. Inflammatory biomarkers in general, and specifically CRP, are known to have a prognostic value in COVID-19 patients [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ]. The availability of the CRP and CBC, in comparison to other biomarkers, is even more pronounced when considering that both are available as a point-of-care test that can be completed at the clinic or at the nursing home where the patients reside, at their bedside [ 33 , 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies demonstrated the usefulness of CRP and blood count as prognostic biomarkers in patients who were admitted to the hospital with COVID-19 infection [ 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ]. However, all of these studies referred to the adult population as one group and did not examine the association between these biomarkers and adverse outcomes in sub-populations.…”

Section: Introductionmentioning

confidence: 99%

Age-Dependent Biomarkers for Prediction of In-Hospital Mortality in COVID-19 Patients

Feigin

Levinson

Wasserman

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Several biomarkers and models have been proposed to predict in-hospital mortality among COVID-19 patients. However, these studies have not examined the association in sub-populations. The present study aimed to identify the association between the two most common inflammatory biomarkers in the emergency department and in-hospital mortality in subgroups of patients. Methods: A historical cohort study of adult patients who were admitted to acute-care hospital between March and December 2020 and had a diagnosis of COVID-19 infection. Data on age, sex, Charlson comorbidity index, white blood cell (WBC) count, C-reactive protein (CRP), and in-hospital mortality were collected. Discrimination ability of each biomarker was observed and the CHAID method was used to identify the association in subgroups of patients. Results: Overall, 762 patients (median age 70.9 years, 59.7% males) were included in the study. Of them, 25.1% died during hospitalization. In-hospital mortality was associated with higher CRP (median 138 mg/L vs. 85 mg/L, p < 0.001), higher WBC count (median 8.5 vs. 6.6 K/µL, p < 0.001), and higher neutrophil-to-lymphocyte ratio (NLR) (median 9.2 vs. 5.4, p < 0.001). The area under the ROC curve was similar among all biomarkers (WBC 0.643, NLR 0.677, CRP 0.646, p > 0.1 for all comparisons). The CHAID method revealed that WBC count was associated with in-hospital mortality in patients aged 43.1–66.0 years (<11 K/µL: 10.1% vs. 11+ K/µL: 27.9%), NLR in patients aged 66.1–80 years (≤8: 15.7%, >8: 43.3%), and CRP in patients aged 80.1+ years (≤47 mg/L: 18.8%, 47.1–149 mg/L: 43.1%, and 149.1+: 71.7% mortality). Conclusions: WBC, NLR, and CRP present similar discrimination abilities. However, each biomarker should be considered as a predictor for in-hospital mortality in different age groups.

show abstract

Mortality Rate and Biomarker Expression Within COVID-19 Patients Who Develop Acute Ischemic Stroke: a Systematic Review and meta-analysis

Cited by 14 publications

References 60 publications

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

Prevalence Estimates and Risk Factors of Anxiety among Healthcare Workers in Jordan over One Year of the COVID-19 Pandemic: A Cross-Sectional Study

Age-Dependent Biomarkers for Prediction of In-Hospital Mortality in COVID-19 Patients

Contact Info

Product

Resources

About